Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
about
Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.Glucocorticoids and type 2 diabetes: from physiology to pathology11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects.Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children?New perspectives on the development of antiobesity drugs.Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes.Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of (14)C-Labeled Inhibitors of 11β-HSD1.Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.
P2860
Q36211201-1BD83E6F-8B96-4A62-889A-566C900E885EQ36506631-CDC4A6EE-A44C-4927-AD9E-7A6210F1C019Q36967015-DB88B56E-C1EA-40C5-8F27-45A30F991DE7Q37353444-0B26E461-C8D2-4325-BD7D-EEB235389DC5Q38001047-C157DD1B-B6F7-4621-871E-A1AAAC4B18E5Q38397340-509C444F-C17B-43AC-A595-4D3D32D73A88Q38917415-B4CB80D0-B04A-4FA9-9150-D9D4484197FEQ39511775-3F8F54E6-BC37-42F0-AB7F-DBFB4F7BD8F1Q41975049-EA5D7812-73C7-41A7-B941-957ED77136DEQ53119150-4EF34457-5A66-4A78-8FC4-4FAE48FF1BE1
P2860
Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@en
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@nl
type
label
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@en
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@nl
prefLabel
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@en
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetic/pha ...... selective 11β-HSD1 inhibitor.
@en
P2093
Anna Akrami
Brian Smith
Edgar Bautista
Ian McCaffery
John P Gibbs
John Rossi
Katherine Paweletz
Marc R Gastonguay
Maurice G Emery
Megan A Gibbs
P2860
P304
P356
10.1177/0091270010374470
P577
2010-07-27T00:00:00Z